<DOC>
	<DOCNO>NCT01994174</DOCNO>
	<brief_summary>The objective research determine effect anti-VEGF drug ( bevacizumab , ranibizumab aflibercept ) aqueous humor dynamic ( AHD ) patient retinal vascular disease . The underlying hypothesis anti-VEGF drug increase intraocular pressure ( IOP ) increase aqueous inflow , decrease uveoscleral outflow . The specific aim evaluate change produce AHD 3 monthly injection anti VEGF agent .</brief_summary>
	<brief_title>Effect Vascular Endothelial Growth Factor Blockers Aqueous Humor Dynamics</brief_title>
	<detailed_description>Intravitreal injection different anti-VEGF agent bevacizumab ( Avastinï¿½ , Genentech , Inc. , South San Francisco , CA , USA ) ranibizumab ( Lucentisï¿½ ; Genentech , Inc. , South San Francisco , CA , USA ) aflibercept ( Eyleaï¿½ , Regeneron , Tarrytown , NY , USA ) widely common practice treatment choroidal neovascularization retinal vascular disease [ 1 ] . Several ocular systemic adverse event report use anti-VEGF agent [ 7 ] . Elevation intraocular pressure ( IOP ) serious ocular adverse event may associate intravitreal injection anti-VEGF agent . IOP elevation anti-VEGF injection may variable presentation range acute transient post injection elevation development persistent IOP elevation mandate pressure lower therapy [ 8 ] . Patients previously exist glaucoma may higher rate persistent IOP elevation associate intravitreal injection anti-VEGF agent . Good et al , report rate persistent IOP elevation intravitreal anti-VEGF tobe 33 % glaucoma patient versus 3.1 % eye without previous diagnosis ofglaucoma [ 9 ] . Tseng et al , report 25 eye sustain elevation IOP serial intravitreal injection anti-VEGF agent ( mean = 20injections ) . All 25 eye normotensive prior study 23 previously diagnose glaucoma [ 10 ] . Multicenter clinical trial study intravitreal injection anti-VEGF agent , MARINA ANCHOR ranibizumab , VISION pegaptanib PACORES bevacizumab , show sustain IOP elevation intravitreal injection study agent [ 12-15 ] . However , subgroup analysis data MARINA ANCHOR trial show least 6 mm Hg increase IOP baseline 2.1 % eye MARINA trial 3.6 % eye ANCHOR trial [ 16 ] . A retrospective chart review 207 patient 6-months follow period serial intravitreal injection anti-VEGF report IOP elevation great 5 mm Hg 2 consecutive visit compare baseline 11.6 % treated eye versus 5.3 % control eye [ 17 ] . The pathophysiology report IOP elevation associate intravitreal injection anti-VEGF unknown . Anti-VEGF compound might increase aqueous humor inflow breakdown blood-aqueous barrier reduce uveoscleral outflow ciliary body vasculature . These potential change could translate elevate IOP glaucoma .</detailed_description>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Subjects must least 19 year age old Ability give inform consent attend study visit Patients establish diagnosis retinal vascular disease ( diabetic macular edema , neovascular macular degeneration , presume ocular histoplasmosis syndrome , high myopia ) require intravitreal injection antiVEGF drug bevacizumab , ranibizumab aflibercept likely need three monthly dos . Patients receive intravitreal injection within 3 month study entry No previous establish diagnosis glaucoma consequently previous history Argon Laser Trabeculoplasty ( ALT ) Selective Laser Trabeculoplasty ( SLT ) . No previous history ocular surgery Patients plan unlikely require elective ocular surgical laser procedure within study duration Open angle anterior chamber clinical examination Ability cooperate aqueous humor dynamic study Contact lenses remove prior topical fluorescein instillation , use end fluorophotometry session Able participate site multivisit study period Age le 18 year age Women pregnant nursing Ocular hypertension glaucoma Narrow angle complete partial closure ( gonioscopy angle &lt; 2 ) Any previous surgical laser procedure Secondary glaucoma include pigmentary , exfoliative , uveitic traumatic glaucoma Any active neovascularization iris , angle , disc retina Diagnosis retinal arterial vein occlusion Chronic recurrent inflammatory eye disease Ocular trauma within past 6 month Ocular infection ocular inflammation past 2 month Any abnormality prevent reliable fluorophotometry either eye , corneal scar severe dry eye result punctuate fluorescein stain cornea Intraocular surgery within 6 month Serious hypersensitivity component study medication risk treatment glaucoma medication , severe asthma emphysema . Use glucocorticoid route . Subject must wash glucocorticoid least 2 week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>vascular</keyword>
	<keyword>retina</keyword>
	<keyword>Anti-VEGF</keyword>
	<keyword>Aqueous humor dynamic</keyword>
</DOC>